Ignite Creation Date:
2024-05-05 @ 11:48 AM
Last Modification Date:
2024-10-26 @ 9:13 AM
Study NCT ID:
NCT00130871
Status:
COMPLETED
Last Update Posted:
2007-02-21
First Post:
2005-08-15
Brief Title:
Levosimendan Pretreatment for Weaning Patients From Cardio-Pulmonary Bypass
Sponsor:
Orion Corporation Orion Pharma
Organization:
Orion Corporation Orion Pharma
Study Overview
Official Title:
Impact of Levosimendan Pretreatment on Weaning From Cardiopulmonary Bypass CPB in Patients With Diminished Left Ventricular Function Before Coronary Artery Bypass Grafting CABG
Status:
COMPLETED
Status Verified Date:
2007-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The study evaluates the efficacy of intravenous levosimendan treatment started during a coronary artery bypass operation to wean patients from a heart lung machine
Detailed Description:
Levosimendan or placebo infusion is started at the time of induction of anesthesia
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None